Torrent Pharma Q1 Result: Net profit grows 20% YoY; US business revenue at ₹308 crore

Its revenue from operations increased 11% year-on-year (YoY) to ₹3,178 crore for Q1 FY26 as compared to ₹2,859 crore in the corresponding quarter of the previous fiscal year.

The operating profit, or earnings before interest, taxes, depreciation, and amortisation (EBITDA), came in at ₹1,032 crore for the quarter under review as against ₹904 crore in Q1 FY25, clocking a jump of 14%. This includes acquisition-related one-off expenses of ₹15 crore.

The margin for Q1 FY26 also expanded 32.5% in contrast to 31.6% YoY.

Torrent Pharma’s India revenue was seen at ₹1,811 crore, rising 11%, led by outperformance in focus therapies. The company’s chronic business also grew at 13%.

The pharma company’s US business revenue jumped 19% to ₹308 crore. Constant currency revenues were at $36 million, up 16% compared to the same period in the previous year. Recent launches have achieved targeted market shares, Torrent Pharma said.

Its revenue from the Brazilian market was at ₹218 crore, up by 11% in the June quarter. The constant currency revenues rose 16% to 143 million Brazilian real.

Aided by the performance of top brands and new launches, Torrent’s Brazil unit’s market share grew 14%.

Germany revenues were at ₹308 crore, gaining 9%. The constant currency revenues at EUR 32 million marginally rose 1%. Torrent Pharma said the growth was impacted due to supply disruption at a third-party supplier.

The pharma company’s board also approved the appointment of Aman Mehta as Managing Director and Whole-time Key Managerial Personnel for the period of 5 years with effect from August 1, 2025, by pre-closing his current appointment as “Wholetime Director.”

With an annual revenue of more than ₹11,500 crore, Torrent Pharma is the flagship firm of the Torrent Group, with group revenues of approximately ₹45,000 crore. It is a speciality-focused company with ~76% of its revenues in India from chronic & sub-chronic therapies. It has a presence in over 50 countries.

Torrent has 8 manufacturing facilities, of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic and overseas markets, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing approximately 750+ scientists.

On Monday, shares of Torrent Pharma settled at ₹3,630 apiece on NSE, rising 0.73%.